Sustained PU.1 Levels Balance Cell-Cycle Regulators to Prevent Exhaustion of Adult Hematopoietic Stem CellsPhilipp B. Staber, Daniel G. Tenen, Felicia Ng et al.|Molecular Cell|2013Cited by 163
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemiaPhilipp B. Staber, Claire Dearden, Marco Herling et al.|Blood|2019Cited by 161
BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemiaCharles Herbaux, Matthew S. Davids, Christoph Kornauth et al.|Blood|2021Cited by 37
Inhibitory NKG2A+ and absent activating NKG2C+ NK cell responses are associated with the development of EBV+ lymphomasHannes Vietzen, Elisabeth Puchhammer‐Stöckl, Philipp B. Staber et al.|Frontiers in Immunology|2023Cited by 16
THE COMBINATION OF VENETOCLAX AND IBRUTINIB IS EFFECTIVE IN RELAPSED/REFRACTORY T‐PROLYMPHOCYTIC LEUKEMIA AND INFLUENCES BCL‐2‐FAMILY MEMBER DEPENDENCIESChristoph Kornauth, Philipp B. Staber, Charles Herbaux et al.|Hematological Oncology|2019Cited by 10